Evidence map›Paper›PMID 37103355›Full record

ArticleMarine drugs2023

Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation.

Khaldoun S Abdelwahed, Abu Bakar Siddique, Hassan Y Ebrahim, Mohammed H Qusa, Ethar A Mudhish, Ashkan H Rad, Mourad Zerfaoui, Zakaria Y Abd Elmageed, Khalid A El Sayed

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. The Olive PhenolicNutrients · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Khaldoun S AbdelwahedSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
Abu Bakar SiddiqueSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
Hassan Y EbrahimSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0000-0001-9057-4582
Mohammed H QusaSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
Ethar A MudhishSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0000-0003-3677-6575
Ashkan H RadSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0000-0002-5748-4160
Mourad ZerfaouiDepartment of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Zakaria Y Abd ElmageedDepartment of Biomedical Sciences, Discipline of Pharmacology, Edward Via College of Osteopathic Medicine, University of Louisiana at Monroe, Monroe, LA 71203, USA.ORCID 0000-0003-4031-0348
Khalid A El SayedSchool of Basic Pharmaceutical and Toxicological Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.ORCID 0000-0002-1456-4064
University of Louisiana at Monroe · USTulane University · US

Funding

Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppressionR21CA263290 · NCI · UNIVERSITY OF LOUISIANA AT MONROE · PI EL SAYED, KHALID A · 2022 to 2023
$344k
NCI NIH HHS R21 CA263290NCI NIH HHS R21CA263290
6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) cells can de novo biosynthesize their own cholesterol and overexpress proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 proved to contribute to mCRPC cell motility since PCSK9 knockdown (KD) in mCRPC CWR-R1ca cells led to notable reductions in cell migration and colony formation. Human tissue microarray results proved a higher immunohistoscore in patients ≥ 65 years old, and PCSK9 proved to be expressed higher at an early Gleason score of ≤7. The fermentation product pseurotin A (PS) suppressed PCSK9 expression, protein-protein interactions with LDLR, and breast and prostate cancer recurrences. PS suppressed migration and colony formation of the CWR-R1ca cells. The progression and metastasis of the CWR-R1ca-Luc cells subcutaneously (sc) xenografted into male nude mice fed a high-fat diet (HFD, 11% fat content) showed nearly 2-fold tumor volume, metastasis, serum cholesterol, low-density lipoprotein cholesterol (LDL-C), prostate-specific antigen (PSA), and PCSK9 levels versus mice fed a regular chow diet. Daily oral PS 10 mg/kg treatments prevented the locoregional and distant tumor recurrence of CWR-R1ca-Luc engrafted into nude mice after primary tumor surgical excision. PS-treated mice showed a significant reduction in serum cholesterol, LDL-C, PCSK9, and PSA levels. These results comprehensively validate PS as an mCRPC recurrence-suppressive lead by modulating the PCSK9-LDLR axis.

Indexed as

Proprotein Convertase 9Prostatic Neoplasms, Castration-ResistantAgedAnimalsCholesterolHumansMaleMiceMice, NudeProprotein ConvertasesProstate-Specific AntigenPyrrolidinonesReceptors, LDLSerine EndopeptidasesCholesterolPCSK9 protein, humanPcsk9 protein, mouseProprotein Convertase 9Proprotein ConvertasesProstate-Specific AntigenpseurotinPyrrolidinonesReceptors, LDLSerine Endopeptidasescastration-resistant prostate cancercholesterolcolony formationfermentationimmunohistoscoreLDLRPCSK9pseurotin Arecurrencetissue microarray

Identifiers

PMID37103355
PMCPMC10144979
OpenAlexW4361301279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.